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Connecting rare genetic variants to neuropsychiatric diseasemechanisms remains a significant challenge. In
this issue of Cell Stem Cell, Pak et al. (2015) combine gene targeting and stem cell technologies to identify a
significant cellular effect of rare penetrant NRXN1 mutations in human neurons, which was found to cause a
defect in neurotransmitter release.The genetic analysis of schizophrenia,
autism spectrum disorders (ASDs), and
other neuropsychiatricdisorders is yielding
a potential trove of molecular clues
to understand pathogenesis and identify
possible therapeutic targets. However,
significant scientific hurdles stand be-
tween emerging genetic findings and their
biological exploitation. Major challenges
are posed by the polygenic architecture
of neuropsychiatric disorders (Schizo-
phrenia Working Group of the Psychiatric
Genomics Consortium, 2014; Purcell
et al., 2014); by the incomplete penetrance
of most disease-associated alleles; and
by their pleiotropic effects, whether single
nucleotide variants (SNVs) or copy number
variants (CNVs) (Lee et al., 2013, Stefans-
son et al., 2014). In this issue of Cell Stem
Cell, Pak et al. (2015) describe the use
of human stem cell-derived excitatory
neurons to study two heterozygous
NRXN1 mutations associated with ASDs
and schizophrenia, one that truncates
and one that deletes the gene.
Damaging NRXN1 mutations result
most often from CNVs in the human
genome. As is typical for CNVs associ-
ated with neuropsychiatric disorders
(Stefansson et al., 2014), those causing
NRXN1 mutations result in multiple dis-
ease phenotypes (Enggaard Hoeffding
et al., 2014). NRXN1 encodes a presynap-
tic cell adhesion molecule, neurexin-1,
which interacts with postsynaptic part-
ners including neuroligins, which have
been independently associated with
ASDs (Su¨dhof, 2008). The precise bound-
aries and other features of CNVs at any
chromosomal locus differ within popula-
tions, making specific alleles very rare.
Given, in addition, the incomplete pene-trance of CNVs including those affecting
NRXN1—and thus the importance of
genetic background—biological analysis
of their effects is markedly benefitted
by use of isogenic cells. Thus Pak et al.
introduced two different heterozygous
conditional NRXN1 mutations into iso-
genic H1 human embryonic stem cell lines
using a recombinant adeno-associated
viral (AAV) vector. The two resulting em-
bryonic stem cell lines were induced to
become excitatory cortical neurons by
forced expression of the transcription
factor Ngn2. During neuronal differen-
tiation, cells were treated with appro-
priate recombinases to yield two different
sets of matching control and NRXN1
mutant neurons. The mutant lines, one a
knockout and the other a truncation,
proved haploinsufficient in neurexin-1
protein, mimicking the situation of pa-
tients with heterozygous loss-of-function
mutations.
Neuronal differentiation, morphology,
and nonsynaptic physiology of the
NRXN1 mutant neurons did not differ
from that of controls; however, both of
the NRXN1 mutant lines demonstrated
significant alterations in synaptic physi-
ology. Pak et al. observed a decrease in
the frequency of miniature excitatory
postsynaptic currents (mEPSCs) without
a change in their amplitude. mEPSCs
result from spontaneous release of sin-
gle neurotransmitter-containing vesicles
from presynaptic terminals. Evoked
EPSCs, in contrast, result from simulta-
neous release of many neurotransmitter-
containing vesicles, typically produced
by an action potential (neuronal firing)
or in vitro by a suprathreshold electrical
or chemical stimulus. The decrease inCell Stem Cell 17, SmEPSC frequency suggested that the
NRXN1 mutant neurons might have fewer
synapses, fewer vesicles per synapse,
or alternatively, a decrease in the proba-
bility of vesicular release. There was no
morphological evidence of alterations in
the number or structure of synapses,
suggesting that reduced neuroexin-1 pro-
tein levels specifically affected synaptic
release mechanisms.
When the authors stimulated the
induced neurons, they observed that
both of the NRXN1 mutations caused a
decrement in EPSC amplitude at the
beginning of a 10 Hz spike train. After
the initially low amplitude, with continued
stimulation, the size of the evoked EPSC
returned to control levels; nonetheless,
the effects on neurotransmitter release
were biologically significant. Pak et al.
also found a 70%–80% increase in pro-
tein, but not mRNA, levels of CASK, a
cytoplasmic scaffolding protein that inter-
acts with neurexin-1, suggesting that neu-
rexin-1 interactions destabilize CASK.
Interestingly, CASK mutations have also
been associatedwith intellectual disability
and ASDs (Asadollahi et al., 2014).
An important strength of this analysis is
the use of an appropriate cell type, a
particularly challenging matter for human
brain disorders. This is because (1) the
brain has myriad cell types; (2) circum-
stances under which living cells can be
obtained from the human brain are
vanishingly rare; and (3) the human cere-
bral cortex has undergone recent evolu-
tionary change, limiting the utility of ani-
mal models as a source of fully relevant
cells. Indeed the highly significant abnor-
mality in stimulus-dependent neurotrans-
mitter release that Pak et al. found ineptember 3, 2015 ª2015 Elsevier Inc. 253
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observed in primary cultures of cortical
neurons from heterozygous or homozy-
gous NRXN1a knockout mice (see their
Supplemental Information). Such species
differences have important implications
not only for pathophysiologic studies but
also for drug discovery. Insofar as the
correction of cellular defects, such as
those reported here, become a basis for
development of neuropsychiatric thera-
peutics, it will be critical to identify and
employ the ‘‘right’’ cells for use in as-
says—not only with respect to species,
but also with respect to specific neuronal
or glial cell type. Without recent advances
in stem cell biology that have paralleled
progress in genomics, the ability to
progress from neuropsychiatric-disor-
der-associated gene lists to informative
biology would be very much limited
(McCarroll and Hyman 2013).
The use of isogenic cell lines with
appropriate control conditions makes
the identification of a robust synaptic
defect convincing. However, given the
importance of genetic background in
penetrance and expressivity of ASD-
and schizophrenia-associated CNVs,
future analyses would benefit from com-
parisons that added additional isogenic
lines. Indeed when robust phenotypic
differences can be found, as with these
NRXN1 mutations, it would also be
worth making comparisons with neurons
derived from patients with similar muta-
tions. While the overall genetic differ-
ences between lines might prove insuper-254 Cell Stem Cell 17, September 3, 2015 ª2ably confounding, it is also possible that
comparisons could inform the generaliz-
ability of a particular human cellular model
as an assay for drug discovery. In one
speculative scenario that takes an anal-
ogy from oncology (recognizing differ-
ences from the penetrant somatic muta-
tions that characterize cancer), it might
be possible to target treatments for
neuropsychiatric disorders to the correc-
tion of pathologic cellular phenotypes
even when the causative mutations pro-
duce diverse cognitive and behavioral
phenotypes in patients.
Another caveat is important. Biological
study of most of the coding variants that
have been identified by whole-exome
sequencing, for example in schizophrenia
(Purcell et al., 2014), will be more difficult
than studying inactivating mutations of
NRXN1. The penetrance of most such
variants is quite modest, and their rarity
means that their disease association will
remain cloudy. Use of isogenic cellular
models to look for their biological effects
would likely need to be engineered with
‘‘sensitized’’ genetic backgrounds likely
gleaned from patients. One initial strategy
might be to look for shared biological ef-
fects using allelic series of rare coding
variants in genes already known to be
disease associated by GWAS. Even
against ‘‘risky’’ genetic backgrounds, the
biological effects of most rare coding var-
iants may be far less robust than those
described here for NRXN1. However
these technologies are ultimately de-
ployed, Pak et al. (2015) have taken an015 Elsevier Inc.important step in the analysis of rare vari-
ations associated with neuropsychiatric
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